Importance: The fact that individuals with @entity161 have high @entity65 and mortality is well established. However, risk status and moderators or mediators in the earliest stages of illness are less clear. Objective: To assess cardiometabolic risk in first-episode @entity161 spectrum disorders (FES) and its relationship to illness duration, antipsychotic treatment duration and type, sex, and race/ethnicity. Design, Setting, and @entity1 : Baseline results of the Recovery After an Initial @entity161 Episode (RAISE) study, collected between July 22, 2010, and July 5, 2012, from 34 community mental health facilities without major research, teaching, or clinical FES programs. @entity1 were aged 15 to 40 years, had research-confirmed diagnoses of FES, and had less than 6 months of lifetime antipsychotic treatment. Exposure: Prebaseline antipsychotic treatment was based on the community clinician's and/or @entity1 's decision. Main Outcomes and Measures: Body composition and fasting lipid, @entity413 , and insulin parameters. Results: In 394 of 404 @entity1 with cardiometabolic data (mean [SD] age, 23.6 [5.0] years; mean [SD] lifetime antipsychotic treatment, 47.3 [46.1] days), 48.3% were @entity28 or overweight, 50.8% smoked, 56.5% had @entity2299 , 39.9% had @entity1556 , 10.0% had @entity101 , and 13.2% had @entity209 . @entity5710 ( @entity413 based, 4.0%; hemoglobin A1c based, 15.4%) and @entity6 ( @entity413 based, 3.0%; hemoglobin A1c based, 2.9%) were less frequent. Total @entity146 duration correlated significantly with higher body mass index, fat mass, fat percentage, and waist circumference (all P   <   .01) but not elevated metabolic parameters (except @entity1674 to HDL-C ratio [P   =   .04]). Conversely, antipsychotic treatment duration correlated significantly with higher non-HDL-C, @entity1674 , and @entity1674 to HDL-C ratio and lower HDL-C and systolic blood pressure (all P    <=   .01). In multivariable analyses, @entity1037 was significantly associated with higher @entity1674 , insulin, and insulin resistance, whereas @entity1089 was associated with significantly higher @entity1674 to HDL-C ratio (all P    <=   .02). Conclusions and Relevance: In @entity1 with FES, cardiometabolic risk factors and abnormalities are present early in the illness and likely related to the underlying illness, unhealthy lifestyle, and antipsychotic medications, which interact with each other. Prevention of and early interventions for @entity146 and treatment with lower-risk agents, routine antipsychotic adverse effect monitoring, and smoking cessation interventions are needed from the earliest illness phases.

Cardiometabolic Risk in XXXX With First-Episode @entity161 Spectrum Disorders: Baseline Results From the RAISE-ETP Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'Participants'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obese'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity5710 :: ('MESH:D011236', 'Disease') :: ['Prediabetes'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric illness'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine fumarate'] @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia', 'Schizophrenia'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular morbidity'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome'] @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine'] @entity1556 :: ('MESH:D058246', 'Disease') :: ['prehypertension'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity1 :: (9606,Species) :: ['Patients']
